Automated screening of blood donations for hepatitis C virus RNA using the Qiagen BioRobot 9604 and the Roche COBAS HCV amplicor assay

Vox Sanguinis

Volumn 82, Issue 4, 2002, Pages 169-176

  Grant, P R ^a   Sims, C M ^b   Krieg Schneider, F ^c   Love, E M ^d   Eglin, R ^d   Tedder, R S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b BIO PRODUCTS LABORATORY   (United Kingdom)

^c QIAGEN GMBH   (Germany)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Automation; Blood screening; Hepatitis C virus (HCV)

Indexed keywords

VIRUS RNA;

ARTICLE; AUTOMATION; BLOOD DONOR; BLOOD TRANSFUSION; EXTRACTION; HEPATITIS C VIRUS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCESS DESIGN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA ANALYSIS; SAMPLING; SCREENING TEST; SENSITIVITY ANALYSIS; SHELF LIFE; TECHNOLOGY; UNITED KINGDOM;

BLOOD DONORS; BLOOD TRANSFUSION; DISEASE TRANSMISSION; DNA, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA; SENSITIVITY AND SPECIFICITY;

EID: 0036589027     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2002.00177.x     Document Type: Article

References (24)

1. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The retrovirus epidemiology donor study. N Engl J Med 1996; 334:1685-1690
2. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR: Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68:15-18
3. Soldan K, Barbara J: The risks of infection transmission by blood transfusion in England. J Clin Pathol 1999; 52:405-408
4. Williamson LM, Lowe S, Love EM, Cohen H, Soldan K, McClelland DB, Skacel P, Barbara JA: Serious hazards of transfusion (SHOT) initiative: Analysis of the first two annual reports. BMJ 1999; 319:16-19
5. Busch MP, Rawal BD, Nowicki M, Operskalski EA, Mosley JW. HCV RNA and ALT patterns in seroconverting transfusion recipients, and correlation with donor ALT and RNA. Transfusion 1997; 37:S443-S443
6. Zuckerman M, Wardle J, Mutton K, Tedder R: Hepatitis B immunisation in chronically transfused recipients. Lancet 1995; 346:1565-1566
7. CPMP: The Introduction of Nucleic Acid Amplification Technology (NAT) for the Detection of Hepatitis C Virus RNA in Plasma Pools. 1998; CPMP/BWP/390/97. London, EMEA, 1998
8. DOH: Further Precautionary Measures on Blood Products Announced. 1998, 98/076. London, Department of Health, 1998
9. Mortimer J: Intersecting pools and their potential application in testing donated blood for viral genomes. Vox Sang 1997; 73:93-96
10. DiDomenico N, Link H, Knobel R, Caratsch T, Weschler W, Loewy ZG, Rosenstraus M: COBAS AMPLICOR. Fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. Clin Chem 1996; 42:1915-1923
11. Grant PR, Kitchen A, Barbara JA, Hewitt P, Sims CM, Garson JA, Tedder RS: Effects of handling and storage of blood on the stability of hepatitis C virus RNA. Implications for NAT testing in transfusion practice. Vox Sang 2000; 78:137-142
12. Saldanha J, Heath A, Lelie N, Pisani G, Nubling M, Yu M: Calibration of HCV working reagents for NAT assays against the HCV international standard. The Collaborative Study Group. Vox Sang 2000; 78:217-224
13. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G: Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34:2259-2266
14. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, Urdea M, Sanchez-Pescador R: Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996; 34:901-907
15. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Brown AJ: Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 1990; 64:864-872
16. Paul-Ehrlich-Institut: Results of the phased plan to reduce the infection risk in hepatitis B, C, and HIV in recipients of packed red cell transfusions. Bundesanzeiger 1998; 53:3835-3836
17. Cuijpers HT, Molijn MH, Bos HJ, Peeters AP, Der Poel CL, Lelie PN: Validation of the NucliSens Extractor in combination with the hepatitis C virus Cobas Amplicor 2.0 assay in four laboratories in the Netherlands utilizing nucleic acid amplification technology for blood screening. Vox Sang 2001; 81:12-20
18. Cardoso MS, Koerner K, Hinz W, Lenz C, Prokein S, Rau B, Schwandt A, Kubanek B: Experiences in HCV-NAT screening prior to releasing cellular components by the German red cross blood transfusion service of baden-wurttemberg. Biologicals 1999; 27:281-284
19. Jarvis L, Cleland A, Simmonds P, Dow B, Munro M, Jordan A, Prowse C, Yap PL: Screening blood donations for hepatitis C virus by polymerase chain reaction (letter). Vox Sang 2000; 78:57-58
20. Roth WK, Weber M, Seifried E: Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999; 353:359-363
21. McDonough SH, Giachetti C, Yang Y, Kolk DP, Billyard E, Mimms L: High throughput assay for the simultaneous or separate detection of human immunodeficiency virus (HIV) and hepatitis type C virus (HCV). Infusionsther Transfusionsmed 1998; 25:164-169
22. Seifried E, Roth WK: Prospective survey of HCV, HBV, HIV-1 NAT screening of more than 10 million blood donors in the Red Cross blood service centres in Germany. Transfus Clin Biol 2001; 8: 17s (Abstract S09-001)
23. Japanese Red Cross: NAT screening research group: nationwide NAT screening of HBV, HCV and HIV-1 for blood transfusion in Japan. Transfus Clin Biol 2001; 8:56s (Abstract PDS3-003)
24. Stramer SL, Caglioti S, Strong DM: NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165-1168